Eisai's Rufinamide Estimated User Fee Deadline Is July 2006

The company submitted its NDA for the anti-epileptic on Sept. 9 for the orphan indication of adjunctive therapy for Lennox-Gastaut syndrome and for adjunctive therapy for partial-onset seizures.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet